Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

May is Mental Health Awareness Month, and Dermatology Times is spotlighting the common relationship between skin conditions and struggles with mental health, quality of life, and well-being.

Reviewing Concerns For Mental Health and Well-Being in Dermatologic Conditions

A new review highlighted JAK inhibitors' role in vitiligo treatment, emphasizing varying benefits, facial efficacy, and potential for sustained responses.

JAK Inhibitors Show Favorable Risk-Benefit Profile In Vitiligo, Especially for Facial Cases

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants. 

The new research will compare eblasakimab to dupilumab and lebrikizumab. 

ASLAN Expands Collaboration with Zenyaku to Investigate Eblasakimab’s MOA Compared to Other Biologics in AD 

This recap of skin cancer innovations accompanies the cover story of our May publication.

Skin Cancer Breakthroughs, Prevention, and Treatment Advances During the Past Year

POLL: What is a Precursor to Squamous Cell Carcinoma?

sergign/AdobeStock